fangchinoline has been researched along with Lung Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Ao, W; Chan, WN; Chen, B; Cheung, AHK; He, M; Huang, H; Kang, W; Ke, J; Li, S; Liang, Q; Ma, BBY; Song, Y; To, KF; Xiao, J; Xie, F; Zhan, Y; Zhang, Y; Zhou, S | 1 |
| Chen, JS; Gao, XZ; Guo, X; Han, JL; Liu, C; Sun, H; Sun, JY; Wang, MX; Wang, Z; Zhang, K | 1 |
| Guo, B; Li, X; Su, J; Wang, K; Zhang, T | 1 |
3 other study(ies) available for fangchinoline and Lung Neoplasms
| Article | Year |
|---|---|
Fangchinoline inhibits non-small cell lung cancer metastasis by reversing epithelial-mesenchymal transition and suppressing the cytosolic ROS-related Akt-mTOR signaling pathway.
Topics: Animals; Benzylisoquinolines; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Endothelial Cells; Epithelial-Mesenchymal Transition; Humans; Lung Neoplasms; Mice; Molecular Docking Simulation; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction; TOR Serine-Threonine Kinases | 2022 |
Fangchinoline derivatives inhibits PI3K signaling in vitro and in vivo in non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzylisoquinolines; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Humans; Lung Neoplasms; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt | 2023 |
Fangchinoline as a kinase inhibitor targets FAK and suppresses FAK-mediated signaling pathway in A549.
Topics: Apoptosis; Benzylisoquinolines; Cell Line, Tumor; Cell Proliferation; Focal Adhesion Kinase 1; Humans; Lung Neoplasms; Neoplasm Invasiveness; Phosphorylation; Signal Transduction | 2015 |